Cargando…
Structure and drug binding of the SARS-CoV-2 envelope protein transmembrane domain in lipid bilayers
An essential protein of the SARS-CoV-2 virus, the envelope protein E, forms a homopentameric cation channel that is important for virus pathogenicity. Here we report a 2.1 Å structure and the drug-binding site of E’s transmembrane domain (ETM), determined using solid-state NMR spectroscopy. In lipid...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7718435/ https://www.ncbi.nlm.nih.gov/pubmed/33177698 http://dx.doi.org/10.1038/s41594-020-00536-8 |
_version_ | 1783619492170956800 |
---|---|
author | Mandala, Venkata S. McKay, Matthew J. Shcherbakov, Alexander A. Dregni, Aurelio J. Kolocouris, Antonios Hong, Mei |
author_facet | Mandala, Venkata S. McKay, Matthew J. Shcherbakov, Alexander A. Dregni, Aurelio J. Kolocouris, Antonios Hong, Mei |
author_sort | Mandala, Venkata S. |
collection | PubMed |
description | An essential protein of the SARS-CoV-2 virus, the envelope protein E, forms a homopentameric cation channel that is important for virus pathogenicity. Here we report a 2.1 Å structure and the drug-binding site of E’s transmembrane domain (ETM), determined using solid-state NMR spectroscopy. In lipid bilayers that mimic the endoplasmic-reticulum Golgi intermediate compartment (ERGIC) membrane, ETM forms a five-helix bundle surrounding a narrow pore. The protein deviates from the ideal α-helical geometry due to three phenylalanine residues, which stack within each helix and between helices. Together with valine and leucine interdigitation, these cause a dehydrated pore compared to viroporins of influenza and HIV viruses. Hexamethylene amiloride binds the polar N-terminal lumen whereas acidic pH affects the C-terminal conformation. Thus, the N- and C-terminal halves of this bipartite channel may interact with other viral and host proteins semi-independently. The structure sets the stage for designing E inhibitors as antiviral drugs. |
format | Online Article Text |
id | pubmed-7718435 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
record_format | MEDLINE/PubMed |
spelling | pubmed-77184352021-05-11 Structure and drug binding of the SARS-CoV-2 envelope protein transmembrane domain in lipid bilayers Mandala, Venkata S. McKay, Matthew J. Shcherbakov, Alexander A. Dregni, Aurelio J. Kolocouris, Antonios Hong, Mei Nat Struct Mol Biol Article An essential protein of the SARS-CoV-2 virus, the envelope protein E, forms a homopentameric cation channel that is important for virus pathogenicity. Here we report a 2.1 Å structure and the drug-binding site of E’s transmembrane domain (ETM), determined using solid-state NMR spectroscopy. In lipid bilayers that mimic the endoplasmic-reticulum Golgi intermediate compartment (ERGIC) membrane, ETM forms a five-helix bundle surrounding a narrow pore. The protein deviates from the ideal α-helical geometry due to three phenylalanine residues, which stack within each helix and between helices. Together with valine and leucine interdigitation, these cause a dehydrated pore compared to viroporins of influenza and HIV viruses. Hexamethylene amiloride binds the polar N-terminal lumen whereas acidic pH affects the C-terminal conformation. Thus, the N- and C-terminal halves of this bipartite channel may interact with other viral and host proteins semi-independently. The structure sets the stage for designing E inhibitors as antiviral drugs. 2020-11-11 2020-12 /pmc/articles/PMC7718435/ /pubmed/33177698 http://dx.doi.org/10.1038/s41594-020-00536-8 Text en Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms |
spellingShingle | Article Mandala, Venkata S. McKay, Matthew J. Shcherbakov, Alexander A. Dregni, Aurelio J. Kolocouris, Antonios Hong, Mei Structure and drug binding of the SARS-CoV-2 envelope protein transmembrane domain in lipid bilayers |
title | Structure and drug binding of the SARS-CoV-2 envelope protein transmembrane domain in lipid bilayers |
title_full | Structure and drug binding of the SARS-CoV-2 envelope protein transmembrane domain in lipid bilayers |
title_fullStr | Structure and drug binding of the SARS-CoV-2 envelope protein transmembrane domain in lipid bilayers |
title_full_unstemmed | Structure and drug binding of the SARS-CoV-2 envelope protein transmembrane domain in lipid bilayers |
title_short | Structure and drug binding of the SARS-CoV-2 envelope protein transmembrane domain in lipid bilayers |
title_sort | structure and drug binding of the sars-cov-2 envelope protein transmembrane domain in lipid bilayers |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7718435/ https://www.ncbi.nlm.nih.gov/pubmed/33177698 http://dx.doi.org/10.1038/s41594-020-00536-8 |
work_keys_str_mv | AT mandalavenkatas structureanddrugbindingofthesarscov2envelopeproteintransmembranedomaininlipidbilayers AT mckaymatthewj structureanddrugbindingofthesarscov2envelopeproteintransmembranedomaininlipidbilayers AT shcherbakovalexandera structureanddrugbindingofthesarscov2envelopeproteintransmembranedomaininlipidbilayers AT dregniaurelioj structureanddrugbindingofthesarscov2envelopeproteintransmembranedomaininlipidbilayers AT kolocourisantonios structureanddrugbindingofthesarscov2envelopeproteintransmembranedomaininlipidbilayers AT hongmei structureanddrugbindingofthesarscov2envelopeproteintransmembranedomaininlipidbilayers |